Baricitinib
Orphan DrugFDA Approved, EMA Approved
Contents
Description
Baricitinib is a selective JAK1/JAK2 inhibitor that modulates interferon signaling pathways. It has been investigated for use in type 1 interferonopathies due to its ability to reduce interferon-driven inflammation. The drug is approved for rheumatoid arthritis and has orphan designation for certain autoinflammatory conditions.
Indications & Therapeutic Use
type 1 interferonopathy, autoinflammatory syndromes
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Baricitinib — GNH India
21 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Baricitinib
4 mg/1tablet, film coatedUSA
Barijak
4mgtabletIndia
Barilup
2mgtabletIndia
Barinat 2mg
2mgtabletIndia
Olumiant
EU
Barinat 4
4mgtabletIndia
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Baricitinib
| Generic Name | baricitinib |
| Brands | 1 brand available |
| Active Ingredient | baricitinib |
| Drug Class | type 1 interferonopathy |
| Manufacturer | Eli Lilly and Company |
| Dosage Forms | oral tablet, 2mg, 4mg |
| Medical Code | L04AA37 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT03334396 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes